Oil prices extend losses as traders downplay Russia sanction risks
DUBLIN - Malin Corporation plc (Euronext Growth Dublin:MLC) reported an intrinsic equity value of €9.52 per share as of June 30, 2025, compared to €10.36 at the end of December 2024, according to the company’s interim results released Wednesday.
The life sciences investment company’s overall intrinsic equity value decreased from €195.6 million to €41.3 million during the first half of 2025, primarily due to the divestment of its stake in Poseida and a subsequent €150 million capital return to shareholders in March.
Malin generated approximately €103.4 million from selling its interest in Poseida to Roche in January at $9.00 per share, with potential for additional payments of up to $47.3 million through a contingent value right upon achievement of specific milestones.
The company’s cash position stood at €13.7 million as of June 30, down from €62.1 million at the end of 2024, and has further decreased slightly to €13.4 million as of August 25.
Following the share buyback completed in March, Malin’s issued share capital has been reduced to 4,335,106 ordinary shares, compared to 18,889,274 at the end of 2024.
"Beginning 2025 with the sale of Poseida represented a very significant milestone for Malin in our continuing strategy to deliver maximum value to shareholders," said Fiona Dunlevy, Chief Executive Officer, in the press release.
The company also reported a downward revision to the estimated valuation of its interest in Viamet, noting challenges in the regulatory approval process for extending the targeted patient population for VIVJOA.
Corporate cash operating expenses for the first half of 2025 were €1.4 million, according to the interim report.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.